3-D Matrix (DMTRF) Price & Analysis

5 Followers

DMTRF Stock Chart & Stats

$2.37

-$0.42(-37.84%)

At close: Dec 12 4:00 PM EST

$2.37

-$0.42(-37.84%)

Day’s Range― - ―

52-Week Range$0.69 - $3.96

Previous CloseN/A

Volume900.00

Average Volume (3M)20.00

Market Cap

$267.26M

Enterprise Value$39.00B

Total Cash (Recent Filing)$2.83B

Total Debt (Recent Filing)$600.00M

Price to Earnings (P/E)10.0

Beta0.01

Next Earnings

Sep 16, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)34.88

Shares Outstanding127,981,480

10 Day Avg. Volume0

30 Day Avg. Volume20

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)9.04

Price to Sales (P/S)5.65

P/FCF Ratio166.61

Enterprise Value/Market Cap145.93

Enterprise Value/Revenue3.58

Enterprise Value/Gross Profit4.55

Enterprise Value/Ebitda13.12

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth And Profit Turnaround3‑D Matrix has delivered a durable top‑line ramp with a meaningful inflection to operating profit and net income after multi‑year losses. A sustained revenue trajectory plus documented operating profitability provides the structural basis for continued reinvestment, margin expansion, and reduced funding dependency over the next 2–6 months if execution holds.

Improved Balance Sheet / Lower LeverageThe company materially reduced total debt and increased equity, strengthening capitalization versus prior stressed periods. Lower leverage provides lasting benefits: more financial flexibility, lower interest burden, and higher resilience to clinical or commercialization timelines, which supports steady operations through the medium term.

Proprietary Peptide Technology And Diversified Revenue3‑D Matrix’s proprietary self‑assembling peptide platform underpins multiple medical applications and revenue streams (product sales, licensing, institutional collaborations). This structural IP and diversified commercial model reduce single‑product dependence and support sustainable market penetration and partner monetization over 2–6 months and beyond.

Bears Say

Weak Cash GenerationDespite accounting profitability, operating and free cash flows remain small relative to reported net income, indicating limited cash conversion. Persistent weak cash generation constrains organic reinvestment, leaves ongoing funding needs, and raises the risk that profits may not translate into cash available for growth or debt reduction in the medium term.

Historic Cash Burn And Earnings Quality RiskA multi‑year history of significant cash burn and notes about one‑time or working‑capital effects imply that recent earnings may be partly non‑recurring. This heightens earnings‑quality risk: without consistent FCF conversion, the company may need external funding or face volatility in strategic investment over the next several quarters.

Profitability Consistency And Margin VolatilityAlthough the latest period shows a swing to profitability, historical volatility in margins and prior deep losses indicate the profit recovery may not be durable. Margin swings reflect execution, pricing or cost variability that can reappear, posing a risk to stable earnings and cash flow generation over the medium term.

3-D Matrix News

3-D Matrix and Harvard Achieve Breakthrough in Cardiac Regenerative Therapy

The latest announcement is out from 3-D Matrix ( ($JP:7777) ). 3-D Matrix, Ltd. has achieved a significant...

9M ago

DMTRF FAQ

What was 3-D Matrix Ltd’s price range in the past 12 months?

3-D Matrix Ltd lowest stock price was $0.69 and its highest was $3.96 in the past 12 months.

What is 3-D Matrix Ltd’s market cap?

3-D Matrix Ltd’s market cap is $267.26M.

When is 3-D Matrix Ltd’s upcoming earnings report date?

3-D Matrix Ltd’s upcoming earnings report date is Sep 16, 2026 which is in 54 days.

How were 3-D Matrix Ltd’s earnings last quarter?

3-D Matrix Ltd released its earnings results on Jun 11, 2026. The company reported $0.091 earnings per share for the quarter, beating the consensus estimate of N/A by $0.091.

Is 3-D Matrix Ltd overvalued?

According to Wall Street analysts 3-D Matrix Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does 3-D Matrix Ltd pay dividends?

3-D Matrix Ltd does not currently pay dividends.

What is 3-D Matrix Ltd’s EPS estimate?

3-D Matrix Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does 3-D Matrix Ltd have?

3-D Matrix Ltd has 127,981,480 shares outstanding.

What happened to 3-D Matrix Ltd’s price movement after its last earnings report?

3-D Matrix Ltd reported an EPS of $0.091 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of 3-D Matrix Ltd?

Currently, no hedge funds are holding shares in DMTRF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

3-D Matrix Ltd

3-D Matrix, Ltd. specializes in pioneering self-assembling peptide technology. Its flagship product, PuraMatrix, is an innovative self-assembling peptide hydrogel with diverse applications across medical fields, including regenerative medicine, cell therapy, advanced drug delivery systems, and surgical interventions. This Tokyo-based firm was established in 2004.